WO2012107890A3 - Crystal forms of lurasidone chlorhydrate - Google Patents
Crystal forms of lurasidone chlorhydrate Download PDFInfo
- Publication number
- WO2012107890A3 WO2012107890A3 PCT/IB2012/050573 IB2012050573W WO2012107890A3 WO 2012107890 A3 WO2012107890 A3 WO 2012107890A3 IB 2012050573 W IB2012050573 W IB 2012050573W WO 2012107890 A3 WO2012107890 A3 WO 2012107890A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lurasidone
- chlorhydrate
- crystal forms
- schizophrenia
- processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides crystalline forms of lurasidone hydrochloride, processes for their preparation, pharmaceutical compositions comprising them and their use for the treatment of schizophrenia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN340DE2011 | 2011-02-10 | ||
IN340/DEL/2011 | 2011-02-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012107890A2 WO2012107890A2 (en) | 2012-08-16 |
WO2012107890A3 true WO2012107890A3 (en) | 2012-11-01 |
Family
ID=46639005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2012/050573 WO2012107890A2 (en) | 2011-02-10 | 2012-02-08 | Crystalline forms of lurasidone hydrochloride |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012107890A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013030722A1 (en) * | 2011-08-26 | 2013-03-07 | Ranbaxy Laboratories Limited | Crystalline lurasidone hydrochloride |
WO2013121440A1 (en) | 2012-02-13 | 2013-08-22 | Cadila Healthcare Limited | Process for preparing benzisothiazol-3-yl-peperazin-l-yl-methyl-cyclo hexyl-methanisoindol-1,3-dione and its intermediates |
CN102863437A (en) * | 2012-09-04 | 2013-01-09 | 济南百诺医药科技开发有限公司 | Preparation method of lurasidone |
WO2014064714A2 (en) * | 2012-10-22 | 2014-05-01 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for preparation of lurasidone hydrochloride |
CN102911170A (en) * | 2012-11-15 | 2013-02-06 | 苏州第壹制药有限公司 | Method for preparing imide compound hydrochloride |
WO2014102834A2 (en) * | 2012-12-31 | 2014-07-03 | Hetero Research Foundation | Process for lurasidone |
CN105524057A (en) * | 2013-03-06 | 2016-04-27 | 江苏恩华药业股份有限公司 | Lurasidone hydrochloride new crystal form and preparation method thereof |
SI3154967T1 (en) | 2014-06-16 | 2020-11-30 | Johnson Matthey Public Limited Company, | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates |
US10987303B2 (en) | 2018-05-02 | 2021-04-27 | LifeMax Laboratories, Inc. | Extended release suspension formulation of lurasidone |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0464846A1 (en) * | 1990-07-06 | 1992-01-08 | Sumitomo Pharmaceuticals Company, Limited | Imide derivatives, and their production and use |
EP1327440A1 (en) * | 2000-09-22 | 2003-07-16 | Sumitomo Pharmaceuticals Company, Limited | Oral preparations with favorable disintegration characteristics |
EP1652848A1 (en) * | 2003-07-29 | 2006-05-03 | Dainippon Sumitomo Pharma Co., Ltd. | Process for producing imide compound |
EP1884242A1 (en) * | 2005-05-26 | 2008-02-06 | Dainippon Sumitomo Pharma Co., Ltd. | Pharmaceutical composition |
EP1891956A1 (en) * | 2005-06-13 | 2008-02-27 | Dainippon Sumitomo Pharma Co., Ltd. | Solubilization preparation |
-
2012
- 2012-02-08 WO PCT/IB2012/050573 patent/WO2012107890A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0464846A1 (en) * | 1990-07-06 | 1992-01-08 | Sumitomo Pharmaceuticals Company, Limited | Imide derivatives, and their production and use |
EP1327440A1 (en) * | 2000-09-22 | 2003-07-16 | Sumitomo Pharmaceuticals Company, Limited | Oral preparations with favorable disintegration characteristics |
EP1652848A1 (en) * | 2003-07-29 | 2006-05-03 | Dainippon Sumitomo Pharma Co., Ltd. | Process for producing imide compound |
EP1884242A1 (en) * | 2005-05-26 | 2008-02-06 | Dainippon Sumitomo Pharma Co., Ltd. | Pharmaceutical composition |
EP1891956A1 (en) * | 2005-06-13 | 2008-02-27 | Dainippon Sumitomo Pharma Co., Ltd. | Solubilization preparation |
Non-Patent Citations (1)
Title |
---|
COLE, P. ET AL: "Lurasidone hydrochloride : dopamine D2/5-HT2A antagonist treatment of schizophrenia", DRUGS OF THE FUTURE, vol. 33, no. 4, 2008, pages 316 - 322, XP002681381 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012107890A2 (en) | 2012-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012107890A3 (en) | Crystal forms of lurasidone chlorhydrate | |
EP2552203A4 (en) | Compounds and pharmaceutical compositions for the treatment of viral infections | |
IL230830A0 (en) | Cellular compositions for the treatment of retinal degeneration diseases | |
WO2012068441A3 (en) | Intedanib salts and solid state forms thereof | |
PH12015501609A1 (en) | Phenicol antibacterials | |
HUE037747T2 (en) | Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them | |
WO2012070062A3 (en) | Novel polymorph of nilotinib hydrochloride | |
WO2013004995A8 (en) | Pyrimidinone compounds and their use | |
PT2429507T (en) | Phosphate-free pharmaceutical composition for the treatment of glaucoma | |
WO2014076712A3 (en) | Lurasidone hydrochloride solid dispersion | |
EP2736905A4 (en) | Intermediate compounds and process for the preparation of lurasidone and salts thereof | |
IL209360A (en) | Pharmaceutical compositions comprising pm00104 for the treatment of multiple myeloma | |
MX2014010433A (en) | Novel crystalline form of sitagliptin sulfate. | |
EP2583969A4 (en) | Novel rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients | |
EP2697238A4 (en) | Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof | |
HK1197235A1 (en) | Dihydropyrazoles, pharmaceutical compositions thereof and their use for the treatment of fertility disorders | |
IL225105A (en) | Heterocyclic compounds, process for their preparation, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments | |
HK1191654A1 (en) | Sterol derivatives, method for preparing same, pharmaceutical compositions containing same and use thereof for the treatment of multiple glioblastomas | |
ECSP13012459A (en) | HIGHLY CRYSTAL VALSARTAN | |
AP2012006280A0 (en) | Synthesis process, and crystalline form of 4-ä3-ÄCis-hexahydrocyclopentaÄCÜpyrrol-2(1H)-YLÜpropoxyübenzamide hydrochloride and pharmaceutical compositions containing it. | |
IN2015DN02109A (en) | ||
WO2011095985A3 (en) | Rasagiline salts and processes for the preparation thereof | |
WO2012038971A3 (en) | Novel polymorphs of febuxostat | |
WO2013114397A3 (en) | Pharmaceutically acceptable salt of brinzolamide and composition thereof | |
EP2529728A4 (en) | Pharmaceutical compositions for the treatment of bacterial infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12704445 Country of ref document: EP Kind code of ref document: A2 |